- Home
- IHS vs JANX Comparison
IHS vs JANX Comparison
Compare IHS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- JANX
- Stock Information
- Founded
- IHS 2001
- JANX 2017
- Country
- IHS United Kingdom
- JANX United States
- Employees
- IHS N/A
- JANX N/A
- Industry
- IHS Telecommunications Equipment
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- JANX Health Care
- Exchange
- IHS Nasdaq
- JANX Nasdaq
- Market Cap
- IHS 1.6B
- JANX 1.6B
- IPO Year
- IHS 2021
- JANX 2021
- Fundamental
- Price
- IHS $5.70
- JANX $25.56
- Analyst Decision
- IHS Strong Buy
- JANX Strong Buy
- Analyst Count
- IHS 5
- JANX 7
- Target Price
- IHS $7.60
- JANX $94.29
- AVG Volume (30 Days)
- IHS 883.8K
- JANX 929.3K
- Earning Date
- IHS 05-16-2025
- JANX 05-08-2025
- Dividend Yield
- IHS N/A
- JANX N/A
- EPS Growth
- IHS N/A
- JANX N/A
- EPS
- IHS N/A
- JANX N/A
- Revenue
- IHS $1,711,225,000.00
- JANX $9,336,000.00
- Revenue This Year
- IHS $0.51
- JANX N/A
- Revenue Next Year
- IHS $6.34
- JANX $250.58
- P/E Ratio
- IHS N/A
- JANX N/A
- Revenue Growth
- IHS N/A
- JANX 28.12
- 52 Week Low
- IHS $2.44
- JANX $22.52
- 52 Week High
- IHS $5.75
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IHS 67.44
- JANX 37.10
- Support Level
- IHS $4.85
- JANX $24.13
- Resistance Level
- IHS $6.00
- JANX $33.97
- Average True Range (ATR)
- IHS 0.25
- JANX 2.01
- MACD
- IHS 0.08
- JANX -0.61
- Stochastic Oscillator
- IHS 77.36
- JANX 14.53
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.